Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|May 19, 2023

BP Elements

  • BioPharm International's BP Elements, June 2023
  • Volume 2
  • Issue 6

New License Agreement Announced for Next-Generation Base Editing Technology

Author(s)Jill Murphy

The pin-point system is completely modular, allowing for different components to be selected for optimal performance specific to the gene targets.

Revvity, Inc. announced on May 18, 2023, a new license agreement with AstraZeneca for the technology underlying technology in its Pin-point base editing system, which is a next-generation modular gene editing platform with a strong safety profile.

The Pin-point system and the base editing technology is defined as allowing highly efficient, precise single and multi-gene editing without unintended impact on cell viability or functionality. According to the press release, this newer editing system uses a modified Cas enzyme that only marks one strand of the DNA, which allows for a more controlled approach to gene distribution and base correction.

Different from other editing systems, the pin-point system is completely modular, allowing for different components to be selected for optimal performance specific to the gene targets. Additionally, Revvity has also developed a novel proprietary method to leverage the base editing mechanism to insert genes, like creating an allogeneic CAR-T cell therapy by knocking in a CAR while knocking out immune markers at the same time, according to the press release.

“Our fundamental goal for the Pin-point platform is to translate the technology from pre-clinical research into the clinic, and ultimately, impact patient lives,” said Alan Fletcher, PhD, senior vice president, Life Sciences at Revvity, in a press release. “In that vein, we are delighted to announce this non-exclusive agreement with AstraZeneca to support their creation of cell therapies for the treatment of cancer and immune-mediated diseases.”

Source: Revvity


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.